Dishman Pharmaceuticals' stock has extended its gains on Wednesday, touching its intraday high of Rs 321.5 per share, higher by nearly 16% in the morning hours.
The stock rallied owing to the news floated in the market that Dishman Pharmaceuticals & Chemicals Limited had received USFDA approval for its ‘Zejula’ capsules. However, the company clarified that it had not received any such approval, but the company named Tesaro Inc., had received the approval from USFDA for its ‘Zejula’ capsules.
Despite of the clarification coming from Dishman Pharma, the stock is witnessing strong upward movement in the morning hours on Wednesday. Other pharma majors like Cipla and Sun Pharma are trading flat on Wednesday.